I am no expert, but my understanding (referenced obliquely in the article) is that this is not the first drug to target reducing the amyloid beta plaque, that does not show positive results. This is raising the question of whether it's treating a side-effect of the disease, rather than actually treating the disease. In other words, it's not all that surprising anymore that a drug targeting the plaque, does not work well.